

# *Gellan gum and its methacrylated derivatives as in situ gelling mucoadhesive formulations of pilocarpine: In vitro and in vivo studies*

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Agibayeva, L. E., Kaldybekov, D. B., Porfiryeva, N. N., Garipova, V. R., Mangazbayeva, R. A., Moustafine, R. I., Semina, I. I., Mun, G. A., Kudaibergenov, S. E. and Khutoryanskiy, V. V. ORCID: <https://orcid.org/0000-0002-7221-2630> (2020) Gellan gum and its methacrylated derivatives as in situ gelling mucoadhesive formulations of pilocarpine: In vitro and in vivo studies. *International Journal of Pharmaceutics*, 577. 119093. ISSN 0378-5173 doi: 10.1016/j.ijpharm.2020.119093 Available at <https://centaur.reading.ac.uk/89013/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

Published version at: <https://www.sciencedirect.com/science/article/pii/S0378517320300776>

To link to this article DOI: <http://dx.doi.org/10.1016/j.ijpharm.2020.119093>

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

## **CentAUR**

Central Archive at the University of Reading

Reading's research outputs online

**Gellan gum and its methacrylated derivatives as *in situ* gelling mucoadhesive formulations of pilocarpine: *in vitro* and *in vivo* studies**

Laura E. Agibayeva<sup>a,b,1</sup>, Daulet B. Kaldybekov<sup>a,b,1</sup>, Natalia N. Porfiryeva<sup>c</sup>, Venera R. Garipova<sup>c</sup>,  
Rauash A. Mangazbayeva<sup>b</sup>, Rouslan I. Moustafine<sup>c,d</sup>, Irina I. Semina<sup>d</sup>, Grigoriy A. Mun<sup>b</sup>, Sarkyt E.  
Kudaibergenov<sup>e</sup>, Vitaliy V. Khutoryanskiy<sup>a,c,\*</sup>

<sup>a</sup> *Reading School of Pharmacy, University of Reading, Whiteknights, RG6 6AD Reading, United Kingdom*

<sup>b</sup> *Department of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, 050040 Almaty, Kazakhstan*

<sup>c</sup> *Institute of Pharmacy, Kazan State Medical University, 16 Fatykh Amirkhan Street, 420126 Kazan, Russian Federation*

<sup>d</sup> *Central Research Laboratory, Kazan State Medical University, 6/30 Tolstogo Street, 420012 Kazan, Russian Federation*

<sup>e</sup> *Institute of Polymer Materials and Technology, 050013 Almaty, Kazakhstan*

<sup>1</sup>These authors contributed equally.

**\*Corresponding author**

Postal address: Reading School of Pharmacy, University of Reading, Whiteknights, PO Box 224, RG6 6AD Reading, United Kingdom

E-mail address: [v.khutoryanskiy@reading.ac.uk](mailto:v.khutoryanskiy@reading.ac.uk) (V.V. Khutoryanskiy)

Phone: +44(0) 118 378 6119

Fax: +44(0) 118 378 4703

24    **Abstract**

25           Gellan gum was chemically modified by the reaction with methacrylic anhydride to produce  
26 derivatives with 6, 14 and 49 % methacrylation. The structure and substitutions degrees of these  
27 derivatives were confirmed by <sup>1</sup>H NMR- and FTIR-spectroscopy. These derivatives are more  
28 hydrophobic compared to pristine gellan and form turbid solutions in water. *In vitro* study performed  
29 with formulations of sodium fluorescein containing gellan gum and its methacrylated derivatives  
30 indicated that methacrylation enhances their retention on bovine conjunctival mucosa. *In vivo*  
31 experiments with the formulations of pilocarpine hydrochloride containing gellan gum and  
32 methacrylated derivatives have demonstrated that all polymers enhance the drug effect significantly,  
33 but best performance is observed for the polysaccharide with 6% methacrylation.

34    **Keywords:** gellan gum, methacrylation, *in situ* gelling, mucoadhesion, ocular drug delivery,  
35 pilocarpine, glaucoma, wash out<sub>50</sub>.

36

## 37    **1.    Introduction**

38            Glaucoma is a group of ophthalmic conditions accompanied with an increased intraocular  
39    pressure, which may eventually result in a damage of an optic nerve and potentially leads to blindness.  
40    There are two types of this ocular condition called open-angle glaucoma and angle-closure glaucoma.  
41    Unfortunately, glaucoma cannot be fully cured but if medication is administered regularly, it can  
42    control the intraocular pressure and prevent the damage of the optic nerve. There are several types of  
43    therapeutic agents that are used to treat glaucoma, which include prostaglandin analogues, beta-  
44    blockers, carbonic anhydrase inhibitors, sympathomimetics and miotics. All these medications are  
45    administered as eye drops (Moiseev et al., 2019).

46            Pilocarpine is a miotic that opens up an inefficient channel in the trabecular meshwork.  
47    Typically, pilocarpine is used for treatment of angle-closure glaucoma and adult patients with this  
48    condition are recommended to apply pilocarpine eye drops up to 4 times a day to control the  
49    intraocular pressure (British National Formulary, 2018). This requirement for frequent application of  
50    eye drops makes the therapy very inconvenient and less patient compliant. Advanced drug delivery  
51    strategies are needed to reduce the need for such a frequency for ocular administration of pilocarpine.

52            When conventional eye drops are used, drug retention in the ocular environment is generally  
53    very poor (Wilson, 2004). This is related to continuous production of tear fluid, blinking reflex,  
54    nasolacrimal drainage and poor permeability of ocular membranes. Therefore, the bioavailability of  
55    drugs administered via conventional eye drops is less than 5% (Hillery et al., 2001). Ocular  
56    bioavailability of eye drops could be substantially improved when mucoadhesive polymers are used  
57    as a part of the formulation. These materials have the ability to adhere to mucosal tissues on the eye  
58    and ensure better retention of the formulation on ocular surfaces leading to more efficient drug  
59    absorption (Hornof et al, 2003; Ludwig, 2005; Laffleur et al, 2015; Tighsazzadeh et al, 2019).

60            All water-soluble polymers exhibit some mucoadhesive properties (Khutoryanskiy, 2011,  
61    2014). Polyelectrolytes (cationic and anionic) usually are more adhesive than non-ionic polymers.  
62    Adhesiveness of formulations and their retention on ocular tissues also depends on other factors such

63 as polymer molecular weight, chain flexibility, presence of cross-links, rheological properties of eye  
64 drops, etc. (Ludwig, 2005). Some polymers could also be used to formulate *in situ* gelling systems  
65 that are liquids during storage but form viscous gels upon administration on the eye, which leads to  
66 substantial improvements in their retention on ocular surfaces (Thrimawithana et al., 2012; Kirchhof  
67 et al., 2015; Al Khateb et al., 2016; Wu et al, 2019).

68 Gellan is a linear anionic hetero-polysaccharide that consists of tetra-saccharide repeating units  
69 including 1,3-β-D-glucose, 1,4-β-D-glucuronic acid, 1,4-β-D-glucose and 1,4-α-L-rhamnose (Bajaj  
70 et al., 2007; Morris et al., 2012). Gel-forming properties of gellan, as well as its biocompatibility,  
71 allow using this polysaccharide not only in the food and cosmetic industry, but also for biomedical  
72 purposes, including drug delivery (Omoto et al., 1999; Rupenthal et al., 2011a; Ferris et al., 2013;  
73 Osmalek et al., 2014; Kudaibergenov et al, 2019). *In situ* gelling properties of gellan based  
74 formulations have been considered for application in ocular drug delivery in several publications  
75 (Rozier et al., 1997; Carlfors et al., 1998; Paulsson et al., 1999; Balasubramaniam et al., 2003;  
76 Rupenthal et al., 2011a, 2011b; Fernández-Ferreiro et al., 2015). Some attempts were also reported  
77 on chemical modification of gellan aiming to enhance its mucoadhesive properties. Yadav et al.  
78 (2014) synthesised gellan-thioglycolic acid conjugate and established that thiolation of gellan gum  
79 decreased its sensitivity to Ca<sup>2+</sup>-induced gelation. However, formulations based on gellan thioglycolic  
80 acid conjugate containing metronidazole showed 1.82-fold greater mucoadhesive strength compared  
81 to parent polymer. Jalil et al (2019) conjugated gellan gum with 2-(2-amino ethyldisulfanyl) nicotinic  
82 acid and used it for formulating mucoadhesive films for vaginal administration.

83 Recently, Kolawole et al. (2018) reported the possibility of enhancing mucoadhesive properties  
84 of chitosan by its methacrylation. Methacrylated chitosan exhibited greater adhesion to and retention  
85 on porcine bladder mucosa. Methacrylated gellan has previously been used for preparation of  
86 chemically cross-linked hydrogels (Coutinho et al., 2010); however, it has not been explored with  
87 regards to the effect of methacrylation on mucoadhesive properties.

88 This paper reports the synthesis of methacrylated gellan and evaluates the possibility of its  
89 retention on freshly excised bovine conjunctival tissue using fluorescent microscopy *in vitro*. It also  
90 evaluates pilocarpine hydrochloride containing *in situ* gelling formulations with gellan and  
91 methacrylated gellan *in vivo* in rabbits.

## 92 **2. Materials and methods**

### 93 **2.1. Materials**

94 Gellan gum Phytigel™ (GG, MW~1000 kDa), methacrylic anhydride (MA), fluorescein sodium  
95 salt (NaFl) and pilocarpine hydrochloride were purchased from Sigma-Aldrich (Gillingham, UK). All  
96 other chemicals were of analytical grade and used without further purification.

### 97 **2.2. Synthesis of methacrylated gellan gum**

98 Methacrylated gellan gum (MeGG) was synthesised by reacting gellan gum (GG) with  
99 methacrylic anhydride (MA) at various molar ratios to produce derivatives with low (LMeGG),  
100 medium (MMeGG) and high (HMeGG) degrees of substitution using a protocol reported by Coutinho  
101 et al. (2010) with slight modifications. Briefly, 0.5 g (0.672 mmol) GG was dissolved in 100 mL of  
102 deionised water in a round-bottom flask at 90 °C for 30 min under constant stirring until a transparent  
103 homogeneous solution formed. Then, the temperature of the mixture was decreased to 50 °C and the  
104 desired amounts of MA were added dropwise. **Table 1** presents the data on the feed ratios used in  
105 this synthesis. The reaction proceeded at 50 °C and shaken at 100 rpm for 6 h. pH was maintained at  
106 8.0 throughout the reaction by adding 5.0 M sodium hydroxide. The final product was re-dispersed  
107 in distilled water, purified by dialysis against distilled water (5 L; 8 changes) during 48 h using a  
108 dialysis membrane tube (12–14 kDa molecular weight cut-off; Medicell Membranes Ltd, UK),  
109 lyophilised and stored in a fridge for further use.

110

111

112

113

114 **Table 1**

115 Feed ratios for the synthesis of methacrylated gellan gum (MeGG).

Parameters	LMeGG	MMeGG	HMeGG
Concentration of gellan gum (GG)	0.5 g	0.5 g	0.5 g
Amount of methacrylic anhydride	1.035 g (1 mL)	2.59 g (2.5 mL)	4.14 g (4 mL)
Moles of MA per unit mole GG	5.0	12.5	20.0

116

117 **2.3. Nuclear magnetic resonance spectroscopy (<sup>1</sup>H NMR)**118 Solutions of gellan gum and its methacrylated derivatives (0.25% w/v) were prepared in D<sub>2</sub>O.119 Solution of methacrylic anhydride (1% v/v) was prepared in CD<sub>3</sub>Cl. <sup>1</sup>H NMR spectra of samples were

120 recorded using a Bruker DPX 400 MHz NMR-spectrometer (Bruker, UK) at 50 °C.

121 The methyl group (–CH<sub>3</sub>) on the rhamnose ring from GG repeating unit was used as a reference

122 (δ 1.27 ppm) and the degree of substitution (DS%) was quantified using the following equation:

$$DS\% = \frac{\frac{1}{2}I_{double\ bond(methacrylate)}}{n_{OH_{repeating\ unit}} \times \frac{1}{3}I_{CH_3(rhamnose)}} \times 100\% \quad (1)$$

124 where  $I_{double\ bond(methacrylate)}$  is the integration of the double bond proton peak of the methacrylate125 groups and  $I_{CH_3(rhamnose)}$  is the integration of the reference peak with the number of protons in each126 peak, respectively;  $n_{OH_{repeating\ unit}}$  is the number of reactive –OH sites in GG structure.127 **2.4. Fourier transform infra-red (FTIR) spectroscopy**

128 FTIR spectra of unmodified and modified gellan gums were recorded on Nicolet iS5 FTIR

129 spectrometer (Thermo Scientific, UK) using an iD5 attenuated total reflectance (ATR) accessory

130 equipped with a diamond crystal. Samples were scanned from 4000 to 500  $\text{cm}^{-1}$ ; the absorbance mode  
131 was used and the spectral resolution was 4  $\text{cm}^{-1}$ .

## 132 **2.5. Dynamic light scattering (DLS)**

133 Aggregation of unmodified and modified gellan gum was examined using dynamic light  
134 scattering (DLS) with a Zetasizer Nano-NS (Malvern Instruments, UK) at 25 °C. Samples were  
135 prepared by dispersing lyophilised polymers in deionised water to form 0.1; 0.5 and 1 mg/mL  
136 solutions and left stirring overnight. The pH of formed dispersions was adjusted to 2; 4; 6 and 8 by  
137 addition of HCl and NaOH solutions.

## 138 **2.6. *Ex vivo* bovine mucoadhesion studies**

### 139 **2.6.1. Preparation of eye drop solutions**

140 In order to demonstrate the applicability of modified and unmodified *in situ* gelling gellan gum  
141 (GG) formulations for ocular drug delivery, fluorescein sodium salt (NaFl) was employed as a model  
142 compound to load into GG and MeGG solutions. Briefly, 30 mg (0.6% w/v) of GG and its  
143 methacrylated derivatives were dissolved in 5 mL aqueous solutions of NaFl (1 mg/mL in deionised  
144 water) at a constant stirring and room temperature until homogenous solutions formed.

145 Simulated tear fluid (STF) used to wash a mucosal surface was prepared as reported previously  
146 (Lin and Sung, 2000). STF was composed of NaCl (6.7 g),  $\text{NaHCO}_3$  (2.0 g), and  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$  (0.08  
147 g) dissolved in 1000 mL of deionised water (pH 7.4) and the solution was kept at 37 °C throughout  
148 the experiments.

### 149 **2.6.2. Retention on bovine conjunctival mucosa**

150 The mucosal retention of modified and unmodified gellan gum (GG) on *ex vivo* bovine  
151 conjunctival tissues was evaluated using the methodology developed in-house with minor  
152 modifications (Tonglairoum et al., 2016). Whole bovine eyeballs with conjunctivae were acquired  
153 from P.C. Turner Abattoirs (Farnborough, UK) immediately after animal slaughter, packed and  
154 transported to the laboratory in a cold polystyrene container. The tissues were subsequently defrosted

155 upon delivery and bovine eyelids were carefully dissected within 2 h using a sharp blade, avoiding  
156 contact with the mucosal surface. Each eyelid mucosa (palpebral conjunctiva) was rinsed with 1 mL  
157 STF solution, mounted on a glass slide with mucosal side facing upward, placed in Petri dishes,  
158 wrapped with cling film to prevent dehydration and stored in a fridge. All tissues were used within  
159 24 h of retrieval.

160 Experiments were conducted with a conjunctival tissue already mounted on a glass slide placed  
161 on a substrate at an angle of 45° and maintained at 37 °C in an incubator. Aliquots (200 µL) from  
162 NaFl-loaded modified and unmodified gellan gum formulations and free NaFl stock solutions were  
163 aspirated and pipetted onto a 2 × 2 cm<sup>2</sup> piece of conjunctival mucosa and irrigated with STF solution  
164 at a flow rate of 200 µL/min using a syringe pump over 60 min of total washing time. Fluorescence  
165 microscopy images of whole tissue were taken at predetermined time points after each wash using a  
166 Leica MZ10F stereo-microscope (Leica Microsystems, UK) with Leica DFC3000G digital camera at  
167 1.6× magnification and 12 ms exposure time, fitted with a GFP filter (blue, λ<sub>emission</sub> = 520 nm). The  
168 microscopy images were then analysed with ImageJ software by measuring the fluorescence pixel  
169 intensity after each wash with STF. The pixel intensity of the blank samples (i.e. the background  
170 microscopy images recorded for each conjunctival mucosa without a fluorescent test material) was  
171 deducted from each measurement and data were normalised and converted into fluorescent intensity  
172 values using the following equation:

$$173 \quad \text{Fluorescence intensity} = \frac{I - I_b}{I_0 - I_b} \times 100\% \quad (2)$$

174 where  $I_b$  is the background fluorescence intensity of a given tissue sample (a blank sample);  $I_0$  is the  
175 initial fluorescence intensity of that sample (a tissue sample with mucoadhesive test material on it  
176 prior to the start of first wash out); and  $I$  is the fluorescence intensity of that tissue sample with a  
177 mucoadhesive fluorescent material after each wash out cycle.

178 In addition, wash out<sub>50</sub> (WO<sub>50</sub>) values of fluorescent mucoadhesives were quantified *via*  
179 extrapolation of the average wash-off profiles to 50 % using polynomial fitting (5th order) and  
180 Wolfram Alpha (a computational knowledge engine). These WO<sub>50</sub> values are used to evaluate and  
181 compare formulations retention efficacy on mucosal surfaces, which depict the volume of simulated  
182 tear fluid necessary to wash out 50 % of a mucoadhesive formulation from a substrate (Mun et al.,  
183 2016).

184 All measurements were carried out in triplicate and the mean values  $\pm$  standard deviations were  
185 quantified and evaluated statistically.

## 186 **2.7. *In vivo* experiments**

187 Solutions of polymers were prepared by dissolving 0.03 g of each polymer in 5 mL deionised  
188 water. Then 0.05 g of pilocarpine hydrochloride was added to each sample to make 1 % solutions and  
189 these were left stirring overnight before use. *In vivo* experiments with these solutions were conducted  
190 in chinchilla rabbits of either sex (3700–3800 g, n = 4) according to the methodology adapted from  
191 (Lin et al., 2004). These experiments were approved by Kazan State Medical University ethics  
192 committee (approval No.5 from 28th May 2012) and were conducted following the ARVO Statement  
193 for the Use of Animals in Ophthalmic and Visual Research. Prior to experiments, rabbits were housed  
194 in standard cages and allowed free access to food and water. During the experiments, rabbits were  
195 restrained by gently wrapping them in a cotton tissue, where their eyes and eye-lid movements were  
196 not restricted. Eye drops (150  $\mu$ L) were instilled into rabbit's left eye and their right one served as a  
197 control (150  $\mu$ L of water were instilled). Digital images were taken at different time points with a  
198 web-camera and these were processed with ImageJ software to calculate the difference between the  
199 right ( $D_{right}$ , mm) and left ( $D_{left}$ , mm) pupil diameters:

$$200 \quad \Delta = D_{right} - D_{left} \quad (3)$$

201 Each experiment was conducted for 210 min; then areas under the decrease in pupil diameter  
202 versus time profile in 210 mins ( $AUC_{15-210}$ ) were calculated using the trapezoidal rule.

203


## 204 **2.8. Statistical analysis**

205 All measurements were performed in triplicates and data expressed as mean  $\pm$  standard  
206 deviation (unless specified otherwise). Data were compared for significance using two-tailed  
207 Student's *t*-test and a one-way analysis of variance (ANOVA) with GraphPad Prism statistical  
208 analysis software (version 7.0; GraphPad Software Inc.), where  $p < 0.05$  was set as the statistical  
209 significance criterion.

## 210 **3. Results and discussion**

### 211 **3.1. Synthesis of methacrylated gellan gum (MeGG) derivatives**

212 Methacrylated gellan was synthesised by reaction with methacrylic anhydride (**Fig. 1A**).  
213 Following purification by dialysis, methacrylated derivatives were studied using  $^1H$  NMR  
214 spectroscopy (**Fig. 1B**). All four spectra displayed the characteristic peak that corresponds to the  
215 methyl ( $-CH_3$ ) group from rhamnose ring ( $\delta$  1.27 ppm), which was used as a reference (Lu et al,  
216 2019).




217

218 **Figure 1.** Synthesis and characterisation of methacrylated gellan gum (MeGG). (A) Schematic  
 219 illustration of the methacrylation reaction. Please note that schematic structure show only one  
 220 possibility of methacrylic reaction anhydride with  $-\text{CH}_2\text{-OH}$  groups of gellan gum. In reality it could  
 221 react with any OH-group present in gellan gum; (B)  $^1\text{H}$  NMR spectra of gellan gum (GG) with low  
 222 (LMeGG), medium (MMeGG) and high (HMeGG) degrees of methacrylation recorded in  $\text{D}_2\text{O}$  at 50  
 223  $^\circ\text{C}$ . The characteristic methyl peak (a) from rhamnose structural unit and methyl group (b) of the  
 224 methacrylic anhydride (MA) were detected at 1.27 and 1.91 ppm, respectively, and methylenide  
 225 ( $\text{CH}_2=$ ) peaks (c) of MA were identified at 5.72 and 6.13 ppm. Some broadening of methyl peak at  
 226 1.27 ppm could be related to partial aggregation of more hydrophobic methacrylated macromolecules.

227 Methacrylation was confirmed by the appearance of distinctive methacryloyl ( $\text{CH}_2=\text{C}(\text{CH}_3)-$ )  
228 group peaks ( $\delta$  5.72 and 6.13 ppm) and a peak corresponding to the  $-\text{CH}_3$  group of the methacrylate  
229 moieties on the modified GG segment ( $\delta$  1.91 ppm). This is in good agreement with  $^1\text{H}$  NMR data  
230 reported in the literature (Coutinho et al., 2010; Kolawole et al., 2018). The degree of substitution  
231 was quantified by determining the ratio of integrated methyldene group ( $\text{CH}_2=\text{C}$ ) peaks on the  
232 methacrylate conjugate over the  $-\text{CH}_3$  group on the rhamnose ring. The LMeGG, MMeGG and  
233 HMeGG displayed DS at 6, 14 and 49 %, respectively. The yields of methacrylated derivatives were:  
234 LMeGG (31 %), MMeGG (22 %) and HMeGG (11 %). This decrease in the yield shows a similar  
235 trend to the previously reported methacrylated chitosan (Kolawole et al., 2018).

236 The methacrylation of GG was further confirmed by FTIR spectroscopy (**Fig. 2**). The FTIR  
237 spectra of modified and unmodified GG display broad  $-\text{OH}$  stretching peaks appeared above 3000  
238  $\text{cm}^{-1}$  and skeletal vibration involving the  $\text{C}-\text{O}$  stretching at  $1030\text{ cm}^{-1}$ , which are typical for all  
239 polysaccharides. The peaks at  $1220$ ,  $1300$ - $1470\text{ cm}^{-1}$  are due to  $\text{C}-\text{C}$  stretching and  $\text{CH}$  bending,  
240 respectively. The characteristic double bond peak signal observed in the spectra of methacrylated  
241 derivatives at  $1630\text{ cm}^{-1}$  represents  $\text{C}=\text{C}$  stretching in methacrylate moiety of GG, while the  
242 absorption band at  $1715\text{ cm}^{-1}$  attributed to the carbonyl ( $\text{C}=\text{O}$ ) stretching confirming the chemical  
243 modification of GG and growth of peak intensity with increasing degree of methacrylation. The peaks  
244 at around  $2300\text{ cm}^{-1}$  present in the spectra of all samples are typical for atmospheric carbon dioxide.



**Figure 2.** FTIR spectra of gellan gum (GG) and its methacrylated derivatives (LMeGG, MMeGG and HMeGG)


### Solubility of methacrylated gellan gum in water

Unlike parent GG, methacrylated gellan gum derivatives were not fully soluble in water and formed slightly turbid solutions. This is likely related to a slightly hydrophobic nature of methacryloyl moieties and is in agreement with the observations reported for methacrylated chitosan (Kolawole et al., 2018). The solutions of parent and modified gellan gum were evaluated using dynamic light scattering (DLS) at three different concentrations (0.1, 0.5 and 1 mg/mL) and different pHs (2, 4, 6, 8), which indicated the presence of highly polydisperse aggregates even in solutions of parent gellan gum (Fig. S1 and S2). The highly polydisperse nature of these aggregates and the presence of particles whose sizes are > 1000 nm did limit the applicability of DLS for accurate characterisation of these colloidal dispersions. The presence of large particles in unmodified gellan gum is likely related to the

258 ability of this polysaccharide to form ordered helixes of double strands at low temperatures (Yuguchi  
259 et al., 1993). The tendency to aggregate is increased with methacrylation due to partially hydrophobic  
260 nature of methacryloyl moieties. More substantial aggregation was observed upon increase in  
261 polymer concentrations in all cases and also under very acidic pH (pH 2.0). The aggregation in  
262 strongly acidic solutions is likely related to suppression of carboxylic groups ionisation.

### 263 3.2. Mucoadhesion studies


264 The mucosal retention of unmodified and methacrylated gellan gum formulations containing  
265 fluorescein sodium (NaFl, 1 mg/mL) and free NaFl solution on freshly isolated bovine conjunctival  
266 tissue was evaluated using a wash-off *in vitro* technique with fluorescent detection. This method has  
267 been extensively used by our group to investigate the mucoadhesive properties of various materials  
268 on mucosal surfaces (Irmukhametova et al., 2011; Al Khateb et al., 2016; Tonglairoum et al., 2016;  
269 Kolawole et al., 2018; Porfiryeva et al, 2019). **Fig. 3** shows exemplar fluorescence microphotographs  
270 of the retention of gellan gum and its methacrylated derivatives (LMeGG, MMeGG, HMeGG) and  
271 NaFl (used as a control) on *ex vivo* bovine conjunctival mucosa taken after each washing with STF  
272 solutions (pH 7.4; flow rate 200  $\mu$ L/min) over 60 min.



273

274 **Figure 3.** Exemplary fluorescent microphotographs showing mucosal retention of unmodified and  
 275 methacrylated gellan gum (GG, LMeGG, MMeGG and HMeGG) formulations with fluorescein  
 276 sodium (NaFl), and free NaFl (served as a control) on freshly excised bovine conjunctival tissue as  
 277 washed with simulated tear fluid (pH 7.4; 200 µL/min) over 60 min. Scale bars are 200 µm.

278 The fluorescent images were then analysed using ImageJ software and fluorescence intensity  
 279 values were normalised to 100 % (**Fig. 4**). During mucoadhesion experiments conducted at 37 °C,  
 280 GG and its methacrylated derivatives formed *in situ* gels and the percentage of retention on mucosal  
 281 tissues was estimated. It was revealed that methacrylation enhanced the mucoadhesive properties of  
 282 GG on freshly excised bovine conjunctiva. HMeGG displayed significantly greater retention  
 283 compared to its unmodified GG ( $p < 0.001$ ), LMeGG ( $p < 0.05$ ) and NaFl solution ( $p < 0.0001$ ).



284

285 **Figure 4.** Mucosal retention of fluorescein sodium (NaFl) from GG, HMeGG, MMeGG and LMeGG,  
 286 and NaFl (used as a control) on freshly dissected bovine conjunctival tissue as irrigated with simulated  
 287 tear fluid (pH 7.4; 200 µL/min) over 60 min. All values are the means  $\pm$  standard deviations of  
 288 triplicate experiments. “\*\*\*” depicts statistical significant differences between samples ( $p < 0.001$ ).

289 Moreover, GG and LMeGG formulations exhibited almost the same retention ability ( $p > 0.05$ ).  
 290 They were washed out quicker than HMeGG but showed greater retention than NaFl solution. The  
 291 retention of HMeGG and MMeGG on conjunctival mucosa was found not to be significantly different  
 292 from each other ( $p > 0.05$ ) expressing a similar retention trend and increased fluorescence intensity  
 293 until the end of washing cycles. Additionally, NaFl solution showed significantly lower retention  
 294 capability, approximately 85 % of it was washed out from the mucosal tissue. The remaining NaFl  
 295 could be associated to its ability to stain mucosal surface as it is usually used in clinical practice for  
 296 the diagnosis of ocular disorders (Korb et al., 2008).

297 In this study, the retention of GG, LMeGG, MMeGG and HMeGG on *ex vivo* bovine  
 298 conjunctivae was also determined using a quantitative WO<sub>50</sub> method developed by Mun et al. (2016).



WO<sub>50</sub> describes the volume of bio-relevant fluid required to wash out 50 % of the formulation from the mucosal surfaces. By analysing individual wash-off profiles for each NaFl-loaded GG, LMeGG, MMeGG and HMeGG excipients as well as free NaFl, the WO<sub>50</sub> values were determined: 18 mL ( $R^2 = 0.9934$ ), 23 mL ( $R^2 = 0.9979$ ), 65 mL ( $R^2 = 0.9977$ ), 75 mL ( $R^2 = 0.9988$ ) and 3 mL ( $R^2 = 0.9958$ ), respectively. According to these data, HMeGG has the highest WO<sub>50</sub> value and this demonstrates its superior retention behaviour compared to other samples. This is likely attributed to the fact that methacrylation (similarly to acrylation) enhances the adhesion of GG on conjunctival tissues by forming covalent linkages between C–C double bond of GG methacrylate moieties and thiol groups present in conjunctival mucosa (Davidovich-Pinhas and Bianco-Peled, 2011; Brannigan and Khutoryanskiy, 2017; Kolawole et al., 2018; Porfiryeva et al, 2019). Therefore, these results confirm the retention properties of methacrylated gellan gum, which could also be used as a potential mucoadhesive formulation in the therapy of ocular disorders.

### 3.3. *In vivo* studies

*In vivo* studies were performed in rabbits using formulations of pilocarpine hydrochloride (pilocarpine · HCl) prepared with unmodified and modified gellan gum. Pilocarpine · HCl eye drops are mainly used in the treatment of glaucoma and this drug causes pupil constriction. This allows a non-invasive *in vivo* study where the efficiency of different pilocarpine formulations could be compared. Previously, Lin et al. (2004) have reported an *in vivo* study of pilocarpine formulated using sodium alginate, Pluronic F127 and their mixtures and established that the mixture of two polymers significantly improves the drug efficiency and bioavailability.


An administration of pilocarpine · HCl containing eye drops in rabbits does indeed cause their pupil constriction (**Fig. 5A**), which could be non-invasively measured using image analysis. **Fig. 5B** shows the difference in pupil diameter  $\Delta$  recorded as a function of time following administration of different pilocarpine hydrochloride formulations. Despite the apparent ease of these measurements, there are some limitations related to the reaction of eye pupils to environmental light. Any changes in lighting of the environment could result in quick pupil reaction, which explains relatively high

325 values of error bars recorded in these measurements. Nevertheless, the analysis of these data indicates  
326 that there is a statistically significant difference between pure pilocarpine · HCl drops and the  
327 formulation containing MMeGG ( $p < 0.05$ ), with the later exhibiting a more substantial pupil  
328 response at 180 min of experiment. The formulation containing MMeGG also showed greater  
329 response compared to unmodified gellan gum ( $p < 0.01$ ).



332 **Figure 5.** Exemplary images of rabbit eye with (left eye) and without (right eye) administration of  
333 pilocarpine · HCl formulations (A);  $\Delta_{pupil}$  values recorded in rabbits from 15 to 210 min of  
334 experiment following administration of different pilocarpine · HCl formulations (B). “\*” and “\*\*”  
335 depict statistically significant differences between samples ( $p < 0.05$ ) and ( $p < 0.01$ ), respectively.  
336 All values are the mean  $\pm$  standard error of the mean (n=4).

337 In order to see the overall performance of all five formulations in the time course of experiments  
338 the values of area under the  $\Delta_{pupil}$  versus time profiles in 15–210 min were calculated (**Fig. 6**). These  
339 values showed the difference between these formulations clearer. The formulation containing  
340 unmodified GG did show significantly greater efficiency compared to pure pilocarpine · HCl ( $p <$   
341  $0.05$ ). The formulations containing LMeGG and MMeGG showed even better performance than GG,  
342 which is likely related to their enhanced mucoadhesive properties ( $p < 0.0001$  and  $p < 0.01$ ,  
343 respectively). However, no significant improvements were found when formulation with HMeGG  
344 was used compared to pure pilocarpine · HCl ( $p > 0.05$ ). Also the formulation containing LMeGG  
345 did exhibit significantly greater performance compared to HMeGG ( $p < 0.05$ ). The poor performance  
346 of HMeGG could be related to its more hydrophobic nature due to the highest levels of methacrylated  
347 groups. The difference between *in vitro* retention data and *in vivo* results observed in this work could  
348 also be related to the different active ingredients used in these formulations: sodium fluorescein  
349 versus pilocarpine · HCl. This could additionally be related to many other factors such some  
350 differences in the nature of mucosal surfaces between *ex vivo* bovine tissues and *in vivo* rabbit tissues  
351 (e.g. different thiol content), different tear production *in vivo* versus *in vitro* flow rate used, etc. Also  
352 *in vivo* the polymer interaction with the mucosa could affect drug absorption due to possible inhibition  
353 effects.



**Figure 6.** Area under the  $\Delta_{pupil}$  versus time profiles in 210 min ( $AUC_{15-210}$ ) for various formulations.

“\*”, “\*\*\*” and “\*\*\*\*\*” depict  $p < 0.05$ ,  $p < 0.01$  and  $p < 0.0001$ , respectively, *ns* – no significance.

All values are the means  $\pm$  standard error of the mean ( $n = 4$ ).

#### 4. Conclusions

This study reports the synthesis of methacrylated gellan gum derivatives and their evaluation as potential mucoadhesive excipients for ocular drug delivery. Gellan gum was modified by reaction with methacrylic anhydride in order to improve its mucoadhesive properties. The methacrylation was confirmed using  $^1H$  NMR and FTIR spectroscopic techniques and the degree of substitution was calculated. It was established that methacrylation makes this polysaccharide more hydrophobic. *In vitro* experiments performed using fluorescence technique indicated significant improvement in the retention of formulations with methacrylation of gellan gum on ocular mucosa. *In vivo* experiments conducted with pilocarpine hydrochloride formulations containing gellan gum and methacrylated derivatives indicated greater performance of the polysaccharide with low degree of modification.

## 369 **Acknowledgements**

370 Chemical Analysis Facility (University of Reading) is thanked for providing access to NMR-  
371 spectroscopy instrument. L.E.A., R.A.M and G.A.M acknowledge the Ministry of Education and  
372 Science of the Republic of Kazakhstan for the research grants (No. BR05234619 and No.  
373 BR05236446). D.B.K. acknowledges the Researcher Links Post-Doctoral Mobility Grant (No.  
374 216046068, British Council Newton – Al-Farabi Partnership Programme) and Al-Farabi Kazakh  
375 National University for financial support of his postdoctoral fellowships. V.V.K and S.E.K.  
376 acknowledge the European Union’s Horizon 2020 research and innovation programme under the  
377 Marie Skłodowska-Curie grant agreement Nanopol 823883. V.V.K. and R.I.M. acknowledge the  
378 Ministry of Education and Science of the Republic of Tatarstan (Russia) for “Algarysh” grant. P.C.

## 379 **Appendix A. Supplementary material**

380 The Supplementary Information is available free of charge.

## 381 **Author contributions**

382 The manuscript was written through contributions of all authors. All authors have given  
383 approval to the final version of the manuscript.

## 384 **Notes**

385 The authors declare no conflict of interest.

## 386 **ORCID ID of authors**

387 Laura E. Agibayeva: <https://orcid.org/0000-0002-5058-5305>

388 Daulet B. Kaldybekov: <https://orcid.org/0000-0002-7191-5465>

389 Natalia N. Porfiryeva <https://orcid.org/0000-0002-7110-2093>

390 Rauash A. Mangazbayeva: <https://orcid.org/0000-0003-1876-591X>

391 Rouslan I. Moustafine, <http://orcid.org/0000-0002-0916-2853>

Sarkyt E. Kudaibergenov: <https://orcid.org/0000-0002-1166-7826>

Vitaliy V. Khutoryanskiy: <https://orcid.org/0000-0002-7221-2630>

## REFERENCES

- Al Khateb, K., Ozhmukhametova, E.K., Mussin, M.N., Seilkhanov, S.K., Rakhypbekov, T.K., Lau, W.M., Khutoryanskiy, V. V, 2016. In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery. *Int. J. Pharm.* 502, 70–79. <https://doi.org/10.1016/j.ijpharm.2016.02.027>
- Bajaj, I.B., Survase, S.A., Saudagar, P.S., Singhal, R.S., 2007. Gellan gum: Fermentative production, downstream processing and applications. *Food Technol. Biotechnol.* 45, 341–354.
- Balasubramaniam, J., Kant, S., Pandit, J.K., 2003. In vitro and in vivo evaluation of the Gelrite® gellan gum-based ocular delivery system for indomethacin. *Acta Pharm.* 53, 251–261.
- Brannigan, R.P., Khutoryanskiy, V. V., 2017. Synthesis and evaluation of mucoadhesive acryloyl-quaternized PDMAEMA nanogels for ocular drug delivery. *Colloids Surfaces B Biointerfaces* 155, 538–543. <https://doi.org/10.1016/j.colsurfb.2017.04.050>
- British National Formulary, 2018. BNF 76, September 2018 – March 2019. BMJ Group, London.
- Carlfors, J., Edsman, K., Petersson, R., Jörnving, K., 1998. Rheological evaluation of Gelrite® in situ gels for ophthalmic use. *Eur. J. Pharm. Sci.* 6, 113–119. [https://doi.org/10.1016/S0928-0987\(97\)00074-2](https://doi.org/10.1016/S0928-0987(97)00074-2)
- Coutinho, D.F., Sant, S. V, Shin, H., Oliveira, J.T., Gomes, M.E., Neves, N.M., Khademhosseini, A., Reis, R.L., 2010. Modified gellan gum hydrogels with tunable physical and mechanical properties. *Biomaterials* 31, 7494–7502. <https://doi.org/10.1016/j.biomaterials.2010.06.035>
- Davidovich-Pinhas, M., Bianco-Peled, H., 2011. Physical and structural characteristics of acrylated poly(ethylene glycol)-alginate conjugates. *Acta Biomater.* 7, 2817–2825. <https://doi.org/10.1016/j.actbio.2011.04.001>

417 Fernández-Ferreiro, A., González Barcia, M., Gil-Martínez, M., Vieites-Prado, A., Lema, I.,  
 418 Argibay, B., Blanco Méndez, J., Lamas, M.J., Otero-Espinar, F.J., 2015. In vitro and in vivo  
 419 ocular safety and eye surface permanence determination by direct and Magnetic Resonance  
 420 Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan. *Eur. J. Pharm.*  
 421 *Biopharm.* 94, 342–351. <https://doi.org/10.1016/j.ejpb.2015.06.003>  
 422 Ferris, C.J., Gilmore, K.J., Wallace, G.G., in het Panhuis, M., 2013. Modified gellan gum hydrogels  
 423 for tissue engineering applications. *Soft Matter* 9, 3705–3711.  
 424 <https://doi.org/10.1039/C3SM27389J>  
 425 Hillery, A.M., Lloyd, A.W., Swarbrick, J., 2001. Drug delivery and targeting for pharmacists and  
 426 pharmaceutical scientists. CRC Press, Taylor & Francis, Boca Raton.  
 427 Hornof, M., Weyenberg, W., Ludwig, A., Bernkop-Schnürch, A., 2003. Mucoadhesive ocular insert  
 428 based on thiolated poly(acrylic acid): development and in vivo evaluation in humans. *J.*  
 429 *Controlled Release* 89, 419-428  
 430 <https://www.sciencedirect.com/science/article/pii/S0168365903001354?via%3Dihub>  
 431 Irmukhametova, G.S., Mun, G.A., Khutoryanskiy, V. V, 2011. Thiolated mucoadhesive and  
 432 PEGylated nonmucoadhesive organosilica nanoparticles from 3-  
 433 mercaptopropyltrimethoxysilane. *Langmuir* 27, 9551–9556. <https://doi.org/10.1021/la201385h>  
 434 Jalil, A., Hussain, M., Le N.-M.N., Laffleur, F., Matuszczak, B., Tribus, M., Bernkop-Schnürch,  
 435 A., 2019. S-protected gellan gum: Decisive approach towards mucoadhesive antimicrobial  
 436 vaginal films. *Int. J. Biol. Macromolecules* 130, 148-157.  
 437 Khutoryanskiy, V. V., 2014. Mucoadhesive materials and drug delivery systems, *Mucoadhesive*  
 438 *Materials and Drug Delivery Systems*. John Wiley & Sons, Ltd, Chichester, UK.  
 439 <https://doi.org/10.1002/9781118794203>  
 440 Khutoryanskiy, V. V., 2011. Advances in mucoadhesion and mucoadhesive polymers. *Macromol.*  
 441 *Biosci.* 11, 748–764. <https://doi.org/10.1002/mabi.201000388>  
 442 Kirchhof, S., Goepferich, A.M., Brandl, F.P., 2015. Hydrogels in ophthalmic applications. *Eur. J.*

Pharm. Biopharm. 95, 227–238. <https://doi.org/https://doi.org/10.1016/j.ejpb.2015.05.016>

Kolawole, O.M., Lau, W.M., Khutoryanskiy, V. V, 2018. Methacrylated chitosan as a polymer with enhanced mucoadhesive properties for transmucosal drug delivery. *Int. J. Pharm.* 550, 123–129. <https://doi.org/https://doi.org/10.1016/j.ijpharm.2018.08.034>

Kudaibergenov, S.E., Xu, S., Tatykhanova, G.S., Kudaibergenova, G.M., 2019. Gellan gum immobilized anticancer drugs and gold nanoparticles in nanomedicine. *Academ. J. Polym. Sci.* 2(3), 555588. DOI: 10.19080/AJOP.2019.02.555588.

Korb, D.R., Herman, J.P., Finnemore, V.M., Exford, J.M., Blackie, C.A., 2008. An evaluation of the efficacy of fluorescein, rose bengal, lissamine green, and a new dye mixture for ocular surface staining. *Eye Contact Lens* 34, 61–64. <https://doi.org/10.1097/ICL.0b013e31811ead93>

Laffleur, F., Dachs, S., 2015. Development of novel mucoadhesive hyaluronic acid derivate as lubricant for the treatment of dry eye syndrome. *Ther Deliv.* 6(10),1211-1219. doi: 10.4155/tde.15.55.

Lin, H.-R., Sung, K.C., 2000. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. *J. Control. Release* 69, 379–388. [https://doi.org/https://doi.org/10.1016/S0168-3659\(00\)00329-1](https://doi.org/https://doi.org/10.1016/S0168-3659(00)00329-1)

Lin, H.-R., Sung, K.C., Vong, W.-J., 2004. In situ gelling of alginate/Pluronic solutions for ophthalmic delivery of pilocarpine. *Biomacromolecules* 5, 2358–2365. <https://doi.org/10.1021/bm0496965>

Lu, Y., Zhao, X., Fang, S., 2019. Characterization, antimicrobial properties and coatings application of gellan gum oxidized with hydrogen peroxide. *Foods* 8, 31. doi:10.3390/foods8010031

Ludwig, A., 2005. The use of mucoadhesive polymers in ocular drug delivery. *Adv. Drug Deliv. Rev.* 57, 1595–1639. <https://doi.org/10.1016/j.addr.2005.07.005>

Moiseev, V.R., Morrison, W.J.P., Steele, F., Khutoryanskiy, V.V., 2019. Penetration enhancers in ocular drug delivery. *Pharmaceutics* 11, 131. <https://doi.org/10.3390/pharmaceutics11070321>

Morris, E.R., Nishinari, K., Rinaudo, M., 2012. Gelation of gellan - A review. *Food Hydrocoll.* 28,

373–411. <https://doi.org/10.1016/j.foodhyd.2012.01.004>

Mun, E.A., Williams, A.C., Khutoryanskiy, V. V., 2016. Adhesion of thiolated silica nanoparticles to urinary bladder mucosa: Effects of PEGylation, thiol content and particle size. *Int. J. Pharm.* 512, 32–38. <https://doi.org/10.1016/j.ijpharm.2016.08.026>

Omoto, T., Uno, Y., Asai, I., 1999. The latest technologies for the application of gellan gum, in: Nishinari, K. (Ed.), *Physical Chemistry and Industrial Application of Gellan Gum*. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 123–126. [https://doi.org/10.1007/3-540-48349-7\\_18](https://doi.org/10.1007/3-540-48349-7_18)

Osmalek, T., Froelich, A., Tasarek, S., 2014. Application of gellan gum in pharmacy and medicine. *Int. J. Pharm.* 466, 328–340. <https://doi.org/10.1016/j.ijpharm.2014.03.038>

Paulsson, M., Hägerström, H., Edsman, K., 1999. Rheological studies of the gelation of deacetylated gellan gum (Gelrite®) in physiological conditions. *Eur. J. Pharm. Sci.* 9, 99–105. [https://doi.org/10.1016/S0928-0987\(99\)00051-2](https://doi.org/10.1016/S0928-0987(99)00051-2)

Porfiryeva, N.N., Nasibullin, S.F., Abdullina, S.G., Tukhbatullina, I.K., Moustafine, R.I., Khutoryanskiy, V.V., 2019. Acrylated Eudragit® EPO as a novel polymeric excipient with enhanced mucoadhesive properties for application in nasal drug delivery, *Int. J. Pharm.* 562, 241–248. <https://doi.org/10.1016/j.ijpharm.2019.03.027>

Rozier, A., Mazuel, C., Grove, J., Plazonnet, B., 1997. Functionality testing of gellan gum, a polymeric excipient material for ophthalmic dosage forms. *Int. J. Pharm.* 153, 191–198. [https://doi.org/10.1016/S0378-5173\(97\)00109-9](https://doi.org/10.1016/S0378-5173(97)00109-9)

Rupenthal, I.D., Green, C.R., Alany, R.G., 2011a. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: Physicochemical characterisation and in vitro release. *Int. J. Pharm.* 411, 69–77. <https://doi.org/10.1016/j.ijpharm.2011.03.042>

Rupenthal, I.D., Green, C.R., Alany, R.G., 2011b. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study. *Int. J. Pharm.* 411, 78–85. <https://doi.org/10.1016/j.ijpharm.2011.03.043>

Thrimawithana, T.R., Rupenthal, I.D., Young, S.A., Alany, R.G., 2012. Environment-sensitive

495 polymers for ophthalmic drug delivery. *J. Drug Deliv. Sci. Technol.* 22, 117–124.  
 496 [https://doi.org/https://doi.org/10.1016/S1773-2247\(12\)50015-8](https://doi.org/https://doi.org/10.1016/S1773-2247(12)50015-8)

497 Tighsazzadeh, M., Mitchell, J.C., Boateng, J.S., 2019. Development and evaluation of performance  
 498 characteristics of timolol loaded composite ocular films as potential delivery platforms for  
 499 treatment of glaucoma. *Int. J. Pharm.* 566, 111–125.  
 500 <https://doi.org/10.1016/j.ijpharm.2019.05.059>

501 Tonglairoum, P., Brannigan, R.P., Opanasopit, P., Khutoryanskiy, V. V., 2016. Maleimide-bearing  
 502 nanogels as novel mucoadhesive materials for drug delivery. *J. Mater. Chem. B* 4, 6581–6587.  
 503 <https://doi.org/10.1039/C6TB02124G>

504 Wilson, C.G., 2004. Topical drug delivery in the eye. *Exp. Eye Res.* 78, 737–743.  
 505 <https://doi.org/10.1016/j.exer.2003.10.004>

506 Yadav, S., Ahuja, M., Kumar, A., Kaur, H., 2014. Gellan-thioglycolic acid conjugate: Synthesis,  
 507 characterization and evaluation as mucoadhesive polymer. *Carbohydr. Polym.* 99, 601–607.  
 508 <https://doi.org/10.1016/j.carbpol.2013.08.068>

509 Yuguchi, Y., Mimura, M., Kitamura, S., Urakawa, H., Kajiwara, K., 1993. Structural characteristics  
 510 of gellan in aqueous solution. *Food Hydrocoll.* 7, 373–385.  
 511 [https://doi.org/https://doi.org/10.1016/S0268-005X\(09\)80233-6](https://doi.org/https://doi.org/10.1016/S0268-005X(09)80233-6)

512 Wu, Y., Liu Y., Li, X., Kebebe, D., Zhang, B., Ren, J., Lu, J., Li., J., Du, S., Liu, Z., 2019. Research  
 513 progress of in-situ gelling ophthalmic drug delivery system. *Asian Journal of Pharmaceutical*  
 514 *Sciences*, 14, 1-15.

515